Liraglutide - Medication and Pregnancy KB

Liraglutide

Exposed non-exposed, cohort studies

Study	Country Study period Study design	Data source	Exposure definition	Non-exposure definition	Exposition period	Sample size (exposed/unexposed) Or (case / control)	Remarks	Risk of bias
Broe (Controls unexposed, general pop) 2025	Denmark 2004 - 2017 population based cohort retrospective	Danish national health registries (the Danish Medical Birth registry, the Danish Civil Registration Registry, the Danish National Prescription Registry, the Danish National Patient registry and the Cause of Death Register).	Singleton livebirths whose mothers had filled a prescription for Liraglutide between the first day in the last menstrual period (LMP) and the end of the first trimester (91days after LMP).	unexposed (general population or NOS) Singleton livebirths of women who did not redeem any drug prescription between 90 days prior to LMP and the end of the first trimester.	1st trimester	55 / 482980	Infants with chromosomal abnormalities (ICD-10 codes Q90– Q99) were excluded from all analyses.
Broe (Controls unexposed, general pop) 2025	Denmark 2004 - 2017 population based cohort retrospective		Exposure was determined using the Prescription register that contains individual-level prescription data from all Danish outpatient pharmacies.		1st trimester	55 / 482980
Broe (Controls unexposed, sick) 2025	Denmark 2004 - 2017 population based cohort retrospective	Danish national health registries (the Danish Medical Birth registry, the Danish Civil Registration Registry, the Danish National Prescription Registry, the Danish National Patient registry and the Cause of Death Register).	Singleton livebirths whose mothers had filled a prescription for Liraglutide between the first day in the last menstrual period (LMP) and the end of the first trimester (91days after LMP).	unexposed, sick Singleton livebirths born to women who were treated with the individual drug of interest during the last year before pregnancy, but not during pregnancy.	1st trimester	55 / 53	Infants with chromosomal abnormalities (ICD-10 codes Q90– Q99) were excluded from all analyses.
Broe (Controls unexposed, sick) 2025	Denmark 2004 - 2017 population based cohort retrospective		Exposure was determined using the Prescription register that contains individual-level prescription data from all Danish outpatient pharmacies.		1st trimester	55 / 53
Maya 2025	USA 2016 - 2025 retrospective cohort	The Mass General Brigham, an academic health system with 15 institutions serving the greater Boston area in Massachusetts, USA.	Singleton pregnancies with Liraglutide order in the electronic health record (EHR) between 3 years before and 90 days after conception.	unexposed (general population or NOS) Singleton pregnancies without Glucagon-like peptide-1 receptor agonist (GLP-1RA) medications recorded between 3 years before pregnancy and 90 days after conception.	3 months or more before pregnancy or1st trimester	145 / 435
Maya 2025	USA 2016 - 2025 retrospective cohort		Maternal medications were obtained in the electronic health record (EHR) from the Mass General Brigham Enterprise Data Warehouse and the Mass General Brigham Research. The exposed and unexposed classifications were validated through manual medical record review of a subset of exposed participants.		3 months or more before pregnancy or1st trimester	145 / 435
Westergaard 2025	Denmark 2009 - 2023 population based cohort retrospective	A nationwide observational cohort study of pregnancies in Denmark.	Pregnancies with periconceptional Liraglutide exposure, was as the redemption of a liraglutide or semaglutide prescription (plus or less eight weeks from the calculated date of first date of the last menstruation).	unexposed (general population or NOS) Unexposed propensity score-matched pregnancies.	3 months or more before pregnancy or1st trimester	-9 / -9	Authors provided results for Liraglutide and Semaglutide and for 2 indications (pre-existing diabetes and weight management) => In the class meta-analysis, only 1 result was kept: the most precise: Liraglutide all indications.
Westergaard 2025	Denmark 2009 - 2023 population based cohort retrospective		Lliraglutide or semaglutide prescription (no other details).		3 months or more before pregnancy or1st trimester	-9 / -9

Case-control studies

Study	Country Study period Study design	Data source	Case	Control	Exposition	Exposition period	Sample size (exposed/unexposed) Or (case / control)	Remarks	Risk of bias

Risk of bias: : NA; : low; : moderate; : serious; : critical; : unclear;

Empty. There are no case-control studies available for this drug.

master protocol